Formed to exploit the non-dermatological applications of a patented library of compounds licensed from Galderma. The company focused on small molecule drugs that target major diseases such as cancer and metabolic disorders. In Feb 2003, Incyte Pharmaceuticals (NASDAQ:INCY) completed its acquisition of Maxia.
Maxia Pharma
